5-(4-Hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion

Experimental and Molecular Medicine

Volumn 43, Issue 8, 2011, Pages 471-478

  Choi, Jae Hoon ^a,b   Park, Jong Gil ^b,c   Jeon, Hyung Jun ^b   Kim, Mi Sun ^b   Lee, Mi Ran ^b   Lee, Mi Ni ^b   Sonn, Seongkeun ^b   Kim, Jae Hong ^d   Lee, Mun Han ^c   Choi, Myung Sook ^e   Park, Yong Bok ^f   Kwon, Oh Seung ^g   Jeong, Tae Sook ^h   Lee, Woo Song ^h   Shim, Hyun Bo ^b   Shin, Dong Hae ^b   Oh, Goo Taeg ^b  

^a Hanyang University   (South Korea)

^b Ewha Womans University   (South Korea)

^c Seoul National University   (South Korea)

^d Korea University   (South Korea)

^e Department of Food Science and Nutrition ^*  (South Korea)

^f Kyungpook National University   (South Korea)

^g Korea Institute of Science and Technology   (South Korea)

^h Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Antioxidants; Arachidonate 5 lipoxygenase; Atherosclerosis; Endothelial cells; Macrophages

Indexed keywords

5 (4 HYDROXY 2,3,5 TRIMETHYLBENZYLIDENE) THIAZOLIDINE 2,4 DIONE; ARACHIDONATE 5 LIPOXYGENASE; BENZYLIDENE DERIVATIVE; LEUKOTRIENE B4; LIPID; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CELL FUNCTION; CELL INFILTRATION; CELL MIGRATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME INHIBITION; EX VIVO STUDY; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID BLOOD LEVEL; MACROPHAGE; MALE; MOLECULAR DOCKING; MONOCYTE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT DURATION;

MUS;

EID: 80052164898     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2011.43.8.053     Document Type: Article

References (29)

1. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002;22:443-9
2. Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007;61:663-76
3. Choi JH, Jeon HJ, Park JG, Sonn SK, Lee MR, Lee MN, You HJ, Kim GY, Kim JH, Lee MH, Kwon OS, Nam KH, Kim HC, Jeong TS, Lee WS, Oh GT. Anti-atherogenic effect of Anti-atherogenic activity of HMB-TZD 477 BHB-TZD having inhibitory activities on cyclooxygenase and 5-lipoxygenase in hyperlipidemic mice. Atherosclerosis 2010;212:146-52
4. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004;350:29-37
5. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, Pieper U, Sali A. Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics 2006;Chapter 5:Unit 5.6
6. Friedrich EB, Tager AM, Liu E, Pettersson A, Owman C, Munn L, Luster AD, Gerszten RE. Mechanisms of leukotriene B4--triggered monocyte adhesion. Arterioscler Thromb Vasc Biol 2003;23:1761-7
7. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 2005; 4:664-72
8. Heller EA, Liu E, Tager AM, Sinha S, Roberts JD, Koehn SL, Libby P, Aikawa ER, Chen JQ, Huang P, Freeman MW, Moore KJ, Luster AD, Gerszten RE. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 2005; 112:578-86
9. Huang L, Zhao A, Wong F, Ayala JM, Struthers M, Ujjainwalla F, Wright SD, Springer MS, Evans J, Cui J. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol 2004;24:1783-8
10. Jawien J, Gajda M, Rudling M, Mateuszuk L, Olszanecki R, Guzik TJ, Cichocki T, Chlopicki S, Korbut R. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 2006;36:141-6
11. Jeong TS, Kim JR, Kim KS, Cho KH, Bae KH, Lee WS. Inhibitory effects of multi-substituted benzylidenethiazolidine-2,4-diones on LDL oxidation. Bioorg Med Chem 2004;12:4017-23
12. Kim JM, Lee EK, Park G, Kim MK, Yokozawa T, Yu BP, Chung HY. Morin modulates the oxidative stress-induced NF-kappaB pathway through its anti-oxidant activity. Free Radic Res 2010;44:454-61
13. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 1996;8:477-86
14. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645-55
15. Lötzer K, Jahn S, Kramer C, Hildner M, Nüsing R, Funk CD, Habenicht AJ. 5-Lipoxygenase/cyclooxygenase-2 crosstalk through cysteinyl leukotriene receptor 2 in endothelial cells. Prostaglandins Other Lipid Mediat 2007;84:108-15
16. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002;91:120-6
17. Momose Y, Maekawa T, Yamano T, Kawada M, Odaka H, Ikeda H, Sohda T. Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities. J Med Chem 2002;45:1518-34
18. Neau DB, Gilbert NC, Bartlett SG, Boeglin W, Brash AR, Newcomer ME. The 1.85 A structure of an 8R-lipoxygenase suggests a general model for lipoxygenase product specificity. Biochemistry 2009;48:7906-15
19. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26
20. Sánchez-Galán E, Gómez-Hernández A, Vidal C, MartínVentura JL, Blanco-Colio LM, Muñoz-García B, Ortega L, Egido J, Tuñón J. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res 2009; 81:216-25
21. Sippl MJ. Recognition of errors in three-dimensional structures of proteins. Proteins 1993;17:355-62
22. Skrzypczak-Jankun E, Bross RA, Carroll RT, Dunham WR, Funk MO Jr. Three-dimensional structure of a purple lipoxygenase. J Am Chem Soc 2001;123:10814-20
23. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, Zieske A, Plenz G, Robenek H, Salbach P, Kuhn H, Radmark O, Samuelsson B, Habenicht AJ. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100:1238-43
24. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008; 77:289-312
25. Unangst PC, Connor DT, Cetenko WA, Sorenson RJ, Kostlan CR, Sircar JC, Wright CD, Schrier DJ, Dyer RD. Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. J Med Chem 1994; 37:322-8
26. Vila L. Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med Res Rev 2004; 24:399-424
27. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997;387:620-4
28. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000;192:421-32
29. Zou Y, Kim DH, Jung KJ, Heo HS, Kim CH, Baik HS, Yu BP, Yokozawa T, Chung HY. Lysophosphatidylcholine enhances oxidative stress via the 5-lipoxygenase pathway in rat aorta during aging. Rejuvenation Res 2009;12:15-24